These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 29027522)
41. Degeneration of the centré median-parafascicular complex in Parkinson's disease. Henderson JM; Carpenter K; Cartwright H; Halliday GM Ann Neurol; 2000 Mar; 47(3):345-52. PubMed ID: 10716254 [TBL] [Abstract][Full Text] [Related]
42. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678 [TBL] [Abstract][Full Text] [Related]
43. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590 [TBL] [Abstract][Full Text] [Related]
44. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease. Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051 [TBL] [Abstract][Full Text] [Related]
46. Effects of eldepryl on glial cell proliferation and activation in the substantia nigra and striatum in a rat model of Parkinson's disease. Liu B; Lv C; Zhang J; Liu Y; Sun J; Cheng X; Mao W; Ma Y; Li S Neurol Res; 2017 May; 39(5):459-467. PubMed ID: 28276259 [TBL] [Abstract][Full Text] [Related]
48. The ultra early diagnosis of Parkinson's disease by the enhanced substantia nigra echo. Zhuang JJ; Zheng YH; Xu XW; Zhou L Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4621-6. PubMed ID: 26698260 [TBL] [Abstract][Full Text] [Related]
49. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J; Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908 [TBL] [Abstract][Full Text] [Related]
50. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Jenner P Acta Neurol Scand Suppl; 1993; 146():6-13. PubMed ID: 8333254 [TBL] [Abstract][Full Text] [Related]
51. Defects of cytochrome c oxidase in the substantia nigra of Parkinson's disease: and immunohistochemical and morphometric study. Itoh K; Weis S; Mehraein P; Müller-Höcker J Mov Disord; 1997 Jan; 12(1):9-16. PubMed ID: 8990048 [TBL] [Abstract][Full Text] [Related]
52. [MORPHOMETRIC CHARACTERISTICS OF SUBSTANTIA NIGRA CELLULAR STRUCTURES OF THE HUMAN BRAIN]. Sal’kov VN; Khudoyerkov RM; Voronkov DN Morfologiia; 2016; 149(2):7-10. PubMed ID: 30136787 [TBL] [Abstract][Full Text] [Related]
53. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734 [TBL] [Abstract][Full Text] [Related]
54. Idiopathic Parkinson's disease combined with multiple system atrophy. A clinicopathological report. Hughes AJ; Daniel SE; Lees AJ Mov Disord; 1991; 6(4):342-6. PubMed ID: 1758453 [TBL] [Abstract][Full Text] [Related]
55. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease. Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279 [TBL] [Abstract][Full Text] [Related]
57. [An autopsy case of senile dementia with pathological features of Parkinson's disease]. Oshima K; Tsuchiya K; Iritani S; Niizato K; Akiyama H; Ikeda K; Arai H No To Shinkei; 2004 Jul; 56(7):603-6. PubMed ID: 15379289 [TBL] [Abstract][Full Text] [Related]
58. Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. Ofori E; Pasternak O; Planetta PJ; Burciu R; Snyder A; Febo M; Golde TE; Okun MS; Vaillancourt DE Neurobiol Aging; 2015 Feb; 36(2):1097-104. PubMed ID: 25467638 [TBL] [Abstract][Full Text] [Related]
59. Pathophysiology of transcranial sonography signal changes in the human substantia nigra. Double KL; Todd G; Duma SR Int Rev Neurobiol; 2010; 90():107-20. PubMed ID: 20692497 [TBL] [Abstract][Full Text] [Related]
60. Substantia nigra and Parkinson's disease: a brief history of their long and intimate relationship. Parent M; Parent A Can J Neurol Sci; 2010 May; 37(3):313-9. PubMed ID: 20481265 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]